FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?
Unresectable hepatocellular carcinoma (HCC) is an advanced primary liver malignancy with a poor prognosis. The Food and Drug Administration (FDA) has, to date, approved nivolumab, pembrolizumab, ramucirumab, nivolumab/ipilimumab, atezolizumab/bevacizumab, as well as tremelimumab/durvalumab, as first...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/3/2685 |
| _version_ | 1797624349348331520 |
|---|---|
| author | Iason Psilopatis Christos Damaskos Anna Garmpi Panagiotis Sarantis Evangelos Koustas Efstathios A. Antoniou Dimitrios Dimitroulis Gregory Kouraklis Michail V. Karamouzis Kleio Vrettou Georgios Marinos Konstantinos Kontzoglou Nikolaos Garmpis |
| author_facet | Iason Psilopatis Christos Damaskos Anna Garmpi Panagiotis Sarantis Evangelos Koustas Efstathios A. Antoniou Dimitrios Dimitroulis Gregory Kouraklis Michail V. Karamouzis Kleio Vrettou Georgios Marinos Konstantinos Kontzoglou Nikolaos Garmpis |
| author_sort | Iason Psilopatis |
| collection | DOAJ |
| description | Unresectable hepatocellular carcinoma (HCC) is an advanced primary liver malignancy with a poor prognosis. The Food and Drug Administration (FDA) has, to date, approved nivolumab, pembrolizumab, ramucirumab, nivolumab/ipilimumab, atezolizumab/bevacizumab, as well as tremelimumab/durvalumab, as first- or second-line monoclonal antibodies (mAbs) for unresectable HCC. The present review examines the current state of knowledge, and provides a useful update on the safety and efficacy of these therapeutic agents, thus attempting to define the suitability of each mAb for different patient subgroups. |
| first_indexed | 2024-03-11T09:41:08Z |
| format | Article |
| id | doaj.art-b20eda36697048c8a31fd85571b7fc0e |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T09:41:08Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-b20eda36697048c8a31fd85571b7fc0e2023-11-16T17:00:49ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-01-01243268510.3390/ijms24032685FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?Iason Psilopatis0Christos Damaskos1Anna Garmpi2Panagiotis Sarantis3Evangelos Koustas4Efstathios A. Antoniou5Dimitrios Dimitroulis6Gregory Kouraklis7Michail V. Karamouzis8Kleio Vrettou9Georgios Marinos10Konstantinos Kontzoglou11Nikolaos Garmpis12Department of Gynecology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, GermanyRenal Transplantation Unit, Laiko General Hospital, 11527 Athens, GreeceFirst Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceMolecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceMolecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceN.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceSecond Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceSecond Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceMolecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceDepartment of Cytopathology, Sismanogleio General Hospital, 15126 Athens, GreeceDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceN.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceN.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceUnresectable hepatocellular carcinoma (HCC) is an advanced primary liver malignancy with a poor prognosis. The Food and Drug Administration (FDA) has, to date, approved nivolumab, pembrolizumab, ramucirumab, nivolumab/ipilimumab, atezolizumab/bevacizumab, as well as tremelimumab/durvalumab, as first- or second-line monoclonal antibodies (mAbs) for unresectable HCC. The present review examines the current state of knowledge, and provides a useful update on the safety and efficacy of these therapeutic agents, thus attempting to define the suitability of each mAb for different patient subgroups.https://www.mdpi.com/1422-0067/24/3/2685hepatocellularcarcinomaunresectabletreatmentFDAmonoclonal |
| spellingShingle | Iason Psilopatis Christos Damaskos Anna Garmpi Panagiotis Sarantis Evangelos Koustas Efstathios A. Antoniou Dimitrios Dimitroulis Gregory Kouraklis Michail V. Karamouzis Kleio Vrettou Georgios Marinos Konstantinos Kontzoglou Nikolaos Garmpis FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far? International Journal of Molecular Sciences hepatocellular carcinoma unresectable treatment FDA monoclonal |
| title | FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far? |
| title_full | FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far? |
| title_fullStr | FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far? |
| title_full_unstemmed | FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far? |
| title_short | FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far? |
| title_sort | fda approved monoclonal antibodies for unresectable hepatocellular carcinoma what do we know so far |
| topic | hepatocellular carcinoma unresectable treatment FDA monoclonal |
| url | https://www.mdpi.com/1422-0067/24/3/2685 |
| work_keys_str_mv | AT iasonpsilopatis fdaapprovedmonoclonalantibodiesforunresectablehepatocellularcarcinomawhatdoweknowsofar AT christosdamaskos fdaapprovedmonoclonalantibodiesforunresectablehepatocellularcarcinomawhatdoweknowsofar AT annagarmpi fdaapprovedmonoclonalantibodiesforunresectablehepatocellularcarcinomawhatdoweknowsofar AT panagiotissarantis fdaapprovedmonoclonalantibodiesforunresectablehepatocellularcarcinomawhatdoweknowsofar AT evangeloskoustas fdaapprovedmonoclonalantibodiesforunresectablehepatocellularcarcinomawhatdoweknowsofar AT efstathiosaantoniou fdaapprovedmonoclonalantibodiesforunresectablehepatocellularcarcinomawhatdoweknowsofar AT dimitriosdimitroulis fdaapprovedmonoclonalantibodiesforunresectablehepatocellularcarcinomawhatdoweknowsofar AT gregorykouraklis fdaapprovedmonoclonalantibodiesforunresectablehepatocellularcarcinomawhatdoweknowsofar AT michailvkaramouzis fdaapprovedmonoclonalantibodiesforunresectablehepatocellularcarcinomawhatdoweknowsofar AT kleiovrettou fdaapprovedmonoclonalantibodiesforunresectablehepatocellularcarcinomawhatdoweknowsofar AT georgiosmarinos fdaapprovedmonoclonalantibodiesforunresectablehepatocellularcarcinomawhatdoweknowsofar AT konstantinoskontzoglou fdaapprovedmonoclonalantibodiesforunresectablehepatocellularcarcinomawhatdoweknowsofar AT nikolaosgarmpis fdaapprovedmonoclonalantibodiesforunresectablehepatocellularcarcinomawhatdoweknowsofar |